Cholesterol gene therapy moved a step closer to everyday use this month. A one-time CRISPR infusion lowered LDL cholesterol by more than half in a small human trial that ran for a full year, while a separate DNA-based molecule cut the protein that drives high cholesterol by 87% in liver cells. Neither approach relies on a daily pill.
Cholesterol gene therapy, why statins are not enough for everyone
Statins remain the first-line treatment for high LDL cholesterol, and they are inexpensive and well studied. But a meaningful share of patients cannot tolerate the muscle aches statins can cause, and others reach the drug’s ceiling without hitting their target number.
For that group, doctors already prescribe injectable antibodies that block PCSK9 every two to four weeks. Cholesterol gene therapy asks a more ambitious question: could a single treatment produce the same effect, or a larger one, without repeat dosing? Two separate research teams published new answers to that question in the past two weeks.
Cholesterol gene therapy in a one-year human trial
Cleveland Clinic researchers gave 15 patients with hard-to-treat lipid disorders a single infusion of CTX310, an experimental CRISPR-Cas9 therapy that edits the ANGPTL3 gene inside liver cells.[1] At the highest dose, LDL cholesterol fell 52.5% from baseline and triglycerides fell 47.8%, with both reductions holding steady through 12 months of follow-up.
No serious treatment-related side effects were reported. Three participants had mild, short-lived infusion reactions such as back pain or nausea, and one person’s liver enzymes rose briefly before returning to normal on their own.[2] Researchers called it the first therapy to lower both LDL and triglycerides together by this much in one dose.
A DNA molecule that silences PCSK9
A second team, from the University of Barcelona and the University of Oregon, took a different route. They built short DNA molecules called polypurine reverse-Hoogsteen hairpins, or PPRHs, designed to interfere with the PCSK9 gene rather than cut it.[3] Their most effective candidate reduced PCSK9 protein by 87% in human liver cells.
In genetically modified mice, a single injection of the same molecule lowered cholesterol by 47%. The approach is still in cells and animals, well behind the CRISPR trial, but it points to a second, potentially gentler way to reach the same target without permanently editing DNA.
How cholesterol gene therapy could change treatment
If larger trials confirm these results, the most likely first patients are people with familial hypercholesterolemia or statin intolerance, groups for whom current options already involve frequent injections or persistently high LDL despite treatment.
Gene-editing therapies for other conditions have launched with list prices in the hundreds of thousands of dollars, so cost and insurance coverage will shape who can access this option long before it becomes a mainstream alternative to a statin pill.[2]
These results sit on top of the tighter LDL targets clinicians already use — see our earlier look at what changed in the 2026 ACC/AHA cholesterol guideline for the numbers doctors are now treating to.
Limitations and open questions
The CRISPR trial included only 15 people, and larger, placebo-controlled studies are needed before any regulator can weigh approval. Longer follow-up will also matter, since gene edits are meant to be permanent and rare late-onset effects cannot be ruled out from one year of data.
The DNA-hairpin approach is earlier still, tested only in liver cells and mice rather than people.[3] Readers on a statin already reaching their target LDL number have no reason to change course based on either study; both are aimed at patients current drugs do not fully help.
| Approach | Status and effect on LDL |
|---|---|
| Statins (daily pill) | Standard first-line care; lowers LDL roughly 30–50%; low-cost and generic |
| PCSK9 antibody injections | Approved, given every 2–4 weeks; adds another 50–60% LDL reduction on top of statins |
| CRISPR gene editing (CTX310) | One-time infusion targeting ANGPTL3; LDL down 52.5%, triglycerides down 47.8% at 12 months in 15 patients |
| DNA PPRH molecule | Preclinical; single injection cut PCSK9 87% in liver cells and cholesterol 47% in mice; not yet tested in humans |
References
- Cleveland Clinic Newsroom, “First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year,” Aug 28, 2026.
- American Heart Association Newsroom, “First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides,” 2026.
- ScienceDaily, “DNA treatment cuts bad cholesterol by nearly 50% without statins,” study published in Biochemical Pharmacology (University of Barcelona / University of Oregon), Sept 9, 2026.
